AZD2423

Phase 2Small molecule

AZD2423 is one of 79 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Diabetic PolyneuropathyActive, not recruiting

NeuralgiaActive, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Diabetic PolyneuropathyPhase 2

Active, not recruiting

NeuralgiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Spiriva

Boehringer Ingelheim

Preclinical

15 2

Aclidinium Bromide

AstraZeneca

Preclinical

21 3

AZD2423

AstraZeneca

Phase 2

2 4

Calciferol

Alnylam Pharmaceuticals

Preclinical

—5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

3 6

Duragesic

CCephalon

Preclinical

2 7

Coumadin

AAbbott

Preclinical

1 8

Zoloft

VViatris Specialty LLC

Preclinical

1 9

Antibiotic

Pfizer

Preclinical

1 10

Insulin Therapy

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01153321·71 enrolled

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01215279·63 enrolled

Tics2 trials

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01233830·19 enrolled

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00940212·80 enrolled

Diabetic Polyneuropathy1 trial

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01201317·134 enrolled

Single Dose1 trial

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers

Completed· AstraZeneca logo

AstraZeneca··NCT01223014·6 enrolled

Single Ascending Dose1 trial

AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00970775·32 enrolled

1 more indication

Neuralgia1 trial

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01200524·133 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for AZD2423. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD2423 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD2423. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD2423

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Tics2 trials

Diabetic Polyneuropathy1 trial

Single Dose1 trial

Single Ascending Dose1 trial

Neuralgia1 trial

References

Drug Info

Quick Facts

Related News